Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut bacteria and minerals: a new hope for ulcerative colitis remission?

NCT ID NCT07758335

Disease control Sponsor: National Hepatology & Tropical Medicine Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Sep 17, 2026 · Updated 5 times

Summary

This trial is testing whether adding a Lactobacillus probiotic or a trace element supplement to standard ulcerative colitis treatment can help keep the disease in remission. About 132 adults with mild to moderate ulcerative colitis will be randomly assigned to one of three groups: standard care plus the probiotic, standard care plus the supplement, or standard care alone. The study will measure changes in disease activity and colon healing over six months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lactobacillus acidophilus probiotic and a trace element supplement (zinc, chromium, selenium, copper, iodine, iron, magnesium, molybdenum)
What this could lead to
If adding probiotics or trace elements to standard treatment helps keep ulcerative colitis in remission, it could offer a simple, low-cost way to improve disease control and reduce flare-ups.
What could go wrong
This is a mid-sized trial, and the benefits are uncertain. Probiotics and supplements may not outperform standard care, and individual responses can vary. Safety is monitored, but digestive side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 132 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18-65 years. 2. Patients diagnosed with mild to moderate UC (according to Mayo Score (36) for Ulcerative Colitis). 3. Patients are on standard of care (biological therapy e.g., infliximab ). Exclusion Criteria: 1. Patients with neurological problems including Alzheimer disease and other dementias, multiple sclerosis, Parkinson's disease, history of large stroke, severe psychiatric disease as it may affect their ability to adhere to their medication and the clinical trial rules and their ability to perform the tests and questionnaires involved in the study (37). 2. Patients with communication problems, that can affect their ability to fully understand the purpose of the trial, difficulty in communicating by phone or ability to come in scheduled visits (38). 3. Patients with autoimmune diseases. 4. Patients with colorectal cancer. 5. Patients previously received probiotics or trace elements in the previous month before recruitment. 6. Liver cirrhosis. 7. Chronic kidney disease (CKD) which is defined as an estimated glomerular filtration rate (eGFR) less than 60 ml/min per 1.73 m2, persisting for 3 months or more (39). 8. Pregnancy or Lactation (40) 9. Patients on conventional therapy (5-amino salicylic acid treatment).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for To evaluate the efficacy of lactobacillus probiotics when added to uc standard of care in maintaining remission in uc patients are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

To evaluate the efficacy of lactobacillus probiotics when added to uc standard of care in maintaining remission in uc patients Ulcerative colitis (UC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • NHTMRI(national hepatology and tropical medicine research institute)

    RECRUITING

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.